AI Engines For more Details: Perplexity Kagi Labs You
Lowering Cholesterol: Fluvastatin belongs to a class of medications known as statins, which work by inhibiting the enzyme HMG-CoA reductase involved in cholesterol synthesis. By reducing cholesterol production in the liver, fluvastatin helps lower levels of low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol.
Reducing Triglycerides: In addition to lowering LDL cholesterol, fluvastatin may also have a modest effect on reducing triglyceride levels, another type of fat in the blood that can contribute to cardiovascular risk when elevated.
Increasing High-Density Lipoprotein (HDL) Cholesterol: Fluvastatin may also help increase levels of high-density lipoprotein (HDL) cholesterol, often referred to as "good" cholesterol. HDL cholesterol is beneficial because it helps remove excess cholesterol from the bloodstream and transport it to the liver for excretion.
Preventing Cardiovascular Events: By effectively lowering cholesterol levels, especially LDL cholesterol, fluvastatin helps reduce the risk of cardiovascular events such as heart attacks, strokes, and coronary artery disease in individuals with or at high risk for cardiovascular disease.
Management of Atherosclerosis: Atherosclerosis is a condition characterized by the buildup of plaque (composed of cholesterol, fat, and other substances) in the arteries, leading to narrowing and hardening of the arteries. Fluvastatin, by lowering cholesterol levels, can slow down the progression of atherosclerosis and reduce the risk of complications associated with this condition.
Primary Prevention: Fluvastatin may be prescribed for primary prevention in individuals with moderate to high cardiovascular risk factors but without established cardiovascular disease. It can help lower the risk of developing cardiovascular events in these individuals.
Secondary Prevention: Fluvastatin is also used for secondary prevention in individuals with established cardiovascular disease, such as those who have previously experienced a heart attack, stroke, or other cardiovascular events. It helps reduce the risk of recurrent events and improves overall cardiovascular outcomes.
Dosage Forms: Fluvastatin is available in various formulations, including immediate-release tablets, extended-release tablets, and sustained-release capsules, to provide flexibility in dosing and optimize cholesterol-lowering effects.
Side Effects: Common side effects of fluvastatin may include muscle pain or weakness (myalgia), gastrointestinal disturbances (such as nausea, diarrhea, or constipation), headache, dizziness, and elevated liver enzymes. Rare but serious side effects may include muscle breakdown (rhabdomyolysis) and liver damage.
Drug Interactions: Fluvastatin may interact with other medications, including certain antibiotics, antifungal agents, immunosuppressants, and drugs metabolized by the cytochrome P450 system. It is important to inform healthcare providers about all medications, supplements, and herbal products being taken to avoid potential interactions.
Monitoring: Patients taking fluvastatin may require regular monitoring of cholesterol levels, liver function tests, and muscle symptoms. Adjustments to the dosage or discontinuation of the medication may be necessary based on treatment response and tolerability.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.5 | 0.5 | |
| Acne | 0.3 | 0.3 | 0 |
| ADHD | 3.1 | 0.3 | 9.33 |
| Age-Related Macular Degeneration and Glaucoma | 0.6 | 0.4 | 0.5 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2.3 | 0.22 |
| Allergies | 5.3 | 2.5 | 1.12 |
| Allergy to milk products | 1.7 | 1.6 | 0.06 |
| Alopecia (Hair Loss) | 1.2 | 1.2 | |
| Alzheimer's disease | 4.8 | 3.2 | 0.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.1 | 0.9 | 1.33 |
| Ankylosing spondylitis | 3.8 | 1.2 | 2.17 |
| Anorexia Nervosa | 1.6 | 1.9 | -0.19 |
| Antiphospholipid syndrome (APS) | 1.1 | 0.3 | 2.67 |
| Asthma | 3.9 | 1.8 | 1.17 |
| Atherosclerosis | 2.1 | 0.3 | 6 |
| Atrial fibrillation | 3 | 1.9 | 0.58 |
| Autism | 5.8 | 6.5 | -0.12 |
| Autoimmune Disease | 1.2 | 0.5 | 1.4 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.2 | 2.2 | |
| Bipolar Disorder | 2.1 | 0.6 | 2.5 |
| Brain Trauma | 0.9 | 0.9 | 0 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.9 | 2 | -1.22 |
| Carcinoma | 4.7 | 2.6 | 0.81 |
| Celiac Disease | 1.9 | 3.4 | -0.79 |
| Cerebral Palsy | 1.4 | 0.7 | 1 |
| Chronic Fatigue Syndrome | 3.2 | 3.2 | 0 |
| Chronic Kidney Disease | 3.1 | 0.9 | 2.44 |
| Chronic Lyme | 0.6 | 0.3 | 1 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 1.2 | 0.58 |
| Chronic Urticaria (Hives) | 2 | 0.1 | 19 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 0.7 | 1.71 |
| Cognitive Function | 2.8 | 1.1 | 1.55 |
| Colorectal Cancer | 5.4 | 2 | 1.7 |
| Constipation | 1.5 | 0.1 | 14 |
| Coronary artery disease | 2.1 | 1.1 | 0.91 |
| COVID-19 | 6.8 | 4.8 | 0.42 |
| Crohn's Disease | 6.2 | 3.5 | 0.77 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.2 | 1.3 | -0.08 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 2.3 | 0.9 | 1.56 |
| Denture Wearers Oral Shifts | 1.2 | 1.2 | |
| Depression | 7 | 4.9 | 0.43 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.7 | 1.5 | 0.13 |
| Endometriosis | 3.2 | 1.8 | 0.78 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 3.6 | 1.2 | 2 |
| erectile dysfunction | 1.6 | 0.3 | 4.33 |
| Fibromyalgia | 2 | 0.9 | 1.22 |
| Functional constipation / chronic idiopathic constipation | 3.9 | 1.8 | 1.17 |
| gallstone disease (gsd) | 3.2 | 0.6 | 4.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.3 | 0.9 | 0.44 |
| Generalized anxiety disorder | 2.2 | 1.3 | 0.69 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.3 | 0.5 | 1.6 |
| Graves' disease | 1.9 | 2.5 | -0.32 |
| Gulf War Syndrome | 0.6 | 0.6 | 0 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 2.3 | 1.2 | 0.92 |
| Heart Failure | 4.2 | 0.7 | 5 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.5 | 0.6 | 1.5 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 1.1 | |
| hyperglycemia | 1.5 | 1.1 | 0.36 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 3.6 | 3.2 | 0.13 |
| Hypothyroidism | 0.4 | -0.4 | |
| Hypoxia | 3.7 | 0.3 | 11.33 |
| IgA nephropathy (IgAN) | 1.6 | 1.7 | -0.06 |
| Inflammatory Bowel Disease | 6.2 | 5.4 | 0.15 |
| Insomnia | 1.6 | 1.6 | 0 |
| Intelligence | 1.2 | 1.2 | |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 5.2 | 2.9 | 0.79 |
| ischemic stroke | 2.8 | 0.9 | 2.11 |
| Liver Cirrhosis | 5.3 | 3.4 | 0.56 |
| Long COVID | 4.1 | 5.7 | -0.39 |
| Low bone mineral density | 0.3 | -0.3 | |
| Lung Cancer | 0.9 | 1 | -0.11 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.6 | 1.5 |
| ME/CFS with IBS | 0.6 | 1.3 | -1.17 |
| ME/CFS without IBS | 0.5 | 1.7 | -2.4 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.1 | 1.1 | |
| Metabolic Syndrome | 5.6 | 5.1 | 0.1 |
| Mood Disorders | 6.7 | 4.3 | 0.56 |
| multiple chemical sensitivity [MCS] | 0.6 | 0.1 | 5 |
| Multiple Sclerosis | 5.3 | 3.6 | 0.47 |
| Multiple system atrophy (MSA) | 0.4 | 0.7 | -0.75 |
| myasthenia gravis | 0.9 | 0.2 | 3.5 |
| neuropathic pain | 1.5 | -1.5 | |
| Neuropathy (all types) | 0.4 | 1.6 | -3 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.4 | 2.7 | 0.63 |
| NonCeliac Gluten Sensitivity | 1 | 0.6 | 0.67 |
| Obesity | 6.6 | 5.6 | 0.18 |
| obsessive-compulsive disorder | 4.2 | 1.9 | 1.21 |
| Osteoarthritis | 1.9 | 1.2 | 0.58 |
| Osteoporosis | 1.7 | 1.3 | 0.31 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 5.3 | 4 | 0.32 |
| Polycystic ovary syndrome | 3.7 | 2.3 | 0.61 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.3 | -0.5 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.2 | 0 |
| Primary sclerosing cholangitis | 2.4 | 1.5 | 0.6 |
| Psoriasis | 3.1 | 0.9 | 2.44 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.7 | 2.7 | 1.11 |
| Rosacea | 0.6 | 0.5 | 0.2 |
| Schizophrenia | 5.5 | 2.2 | 1.5 |
| scoliosis | 0.6 | 0.9 | -0.5 |
| Sjögren syndrome | 2.3 | 2.4 | -0.04 |
| Sleep Apnea | 1.9 | 0.7 | 1.71 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2 | 0.2 | 9 |
| Stress / posttraumatic stress disorder | 2.7 | 1.3 | 1.08 |
| Systemic Lupus Erythematosus | 3.2 | 1.5 | 1.13 |
| Tic Disorder | 0.9 | 1.2 | -0.33 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 2.6 | 2.9 | -0.12 |
| Type 2 Diabetes | 5.7 | 5.6 | 0.02 |
| Ulcerative colitis | 5.7 | 3.2 | 0.78 |
| Unhealthy Ageing | 3.5 | 1 | 2.5 |
| Vitiligo | 2 | 0.9 | 1.22 |
